Beta Bionics Announces Participation at Upcoming Investor Conferences
IRVINE, Calif., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that management will present at three upcoming investor conferences (all Eastern Time):
- Wells Fargo 20th Annual Healthcare Conference on Thursday, September 4, 2025 at 3:45pm
- Morgan Stanley 23rd Annual Global Healthcare Conference on Monday, September 8, 2025 at 1:50pm
- Baird 2025 Global Healthcare Conference on Wednesday, September 10, 2025 at 9:40am
The presentations at the Wells Fargo and Morgan Stanley conferences will be webcast live. The link to the webcasts will be available on the Company’s website in the “Investors—Events & Presentations” section at , and will be archived there for future replay following the events.
About Beta Bionics
Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit .
Investor Relations:
Blake Beber
Head of Investor Relations
Media and Public Relations:
Karen Hynes
Vice President of Marketing
Source: Beta Bionics, Inc.
